Pyrazinecarboxamide derivatives as CB1 antagonists

US7629346B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Paul Hebeisen · Basel, CH
• Hans Iding · Rheinfelden (Baden), DE
• Matthias Nettekoven · Weil am Rhein, DE
• Ulrike Obst Sander · Sursee, CH
• Stephan Roever · Inzlingen, DE
• Urs Weiss · Pratteln, CH
• Beat Wirz · Basel, CH

Key dates

• Filing date: May 30, 2007
• Grant date: Dec 8, 2009
• Expiry date: May 30, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the formula I:wherein R1 to R8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.